BlueStone Venture Partners
BlueStone Venture Partners is a Southwest‑rooted, life sciences venture capital firm that invests in early‑stage companies outside traditional US innovation hubs. The firm focuses on transformative platforms in Medical Devices, Diagnostics, Digital Health and Life Science Research Tools, providing growth capital, hands‑on strategic support, and access to industry partners and co‑investors.
Industries
Nr. of Employees
small (1-50)
BlueStone Venture Partners
Portfolio
Referenced on BlueStone portfolio page; news item on securing financing to advance a cell separation platform.
#Life science tools (cell separation)
Referenced on BlueStone portfolio page; received U.S. 510(k) clearance for PlaqueIQ image analysis software.
#Cardiovascular imaging / medical software
Referenced on BlueStone portfolio page; multiple financing and regulatory milestones reported related to GammaTile therapy.
#Medical devices (GammaTile radiation therapy)
Referenced on BlueStone portfolio page; announced commercial availability of NTxscribe and plans for a biomanufacturing facility.
#Biomanufacturing / RNA enabling technologies
Referenced on BlueStone portfolio page; noted acquisition by Exact Sciences in site news.
#Diagnostics
Referenced on BlueStone portfolio page; received FDA Breakthrough Device designation for DCISionRT test.
#Diagnostics (breast cancer risk test)
Referenced on BlueStone portfolio page; news item on securing financing to advance a cell separation platform.
#Life science tools (cell separation)
Referenced on BlueStone portfolio page; received U.S. 510(k) clearance for PlaqueIQ image analysis software.
#Cardiovascular imaging / medical software
Referenced on BlueStone portfolio page; multiple financing and regulatory milestones reported related to GammaTile therapy.
#Medical devices (GammaTile radiation therapy)
Referenced on BlueStone portfolio page; announced commercial availability of NTxscribe and plans for a biomanufacturing facility.
#Biomanufacturing / RNA enabling technologies
Referenced on BlueStone portfolio page; noted acquisition by Exact Sciences in site news.
#Diagnostics
Referenced on BlueStone portfolio page; received FDA Breakthrough Device designation for DCISionRT test.
#Diagnostics (breast cancer risk test)